Bioceres Crop Solutions Corp (BIOX)
Official siteBASIC MATERIALS • AGRICULTURAL INPUTS • NASDAQ
Market Cap: $12.74M
Last updated: Nov 17, 2026 at 4:10 PM ET
Bioceres Crop Solutions Corp (BIOX) Statistics
Bioceres Crop Solutions (BIOX) has a market cap of $12.74M and an enterprise value of $230.74M. Its net debt of $218.00M equals 1710.60% of its market cap. It kept -93.45% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 1710.60% above the market cap, as debt exceeds cash.
| Market Cap | $12.74M |
|---|---|
| Enterprise Value | $230.74M |
| Latest price (Nov 17, 2026) | $0.19 |
Key Dates
| Last Earnings Date | Nov 11, 2026 |
|---|---|
| Fiscal Year End | June |
Valuation Ratios
| P/B Ratio | 0.3x |
|---|---|
| P/FCF Ratio | 0.2x |
Enterprise Valuation
Counting debt and cash, the company is valued at 86.6x EBITDA and 3.2x free cash flow.
| EV / Sales | 0.9x |
|---|---|
| EV / EBITDA | 86.6x |
| EV / FCF | 3.2x |
Price Statistics
The stock is down 88.68% over 52 weeks and trades 36.67% below its 50-day average.
| Beta (1Y) | 2.18 |
|---|---|
| 52-Week Change | -88.68% |
| 1-Month Change | -25.48% |
| 3-Month Change | -54.16% |
| 6-Month Change | -54.75% |
| 5-Year Change | -98.39% |
| Total Return (1Y) | -88.68% |
| Total Return (3Y CAGR) | -74.69% |
| Total Return (5Y CAGR) | -58.72% |
| Max Drawdown (1Y) | -88.95% |
| Max Drawdown (3Y) | -98.63% |
| Sharpe Ratio (1Y) | -2.13 |
| Correlation with SPY (1Y) | 0.30 |
| 50-Day Average | $0.30 |
| 200-Day Average | $0.41 |
| 52-Week Range | $0.19 to $1.73 |
| RSI (14 Days) | 35.5 |
| Average Volume (20 Days) | 223.03K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.81x current liabilities, and total debt is 5.86x shareholder equity.
| Current Ratio | 0.81x |
|---|---|
| Quick Ratio | 0.63x |
| Debt / Equity | 5.86x |
| Debt / EBITDA | 86.26x |
| Interest Coverage | 0.06x |
Returns and Efficiency
Return on invested capital is -15.36% and return on equity is -588.66% over the last 12 months.
| Return on Equity (ROE) | -588.66% |
|---|---|
| Return on Assets (ROA) | -48.84% |
| Return on Invested Capital (ROIC) | -15.36% |
| Return on Capital Employed (ROCE) | -20.18% |
| Asset Turnover | 0.40x |
| Inventory Turnover | 3.20x |
| Receivables Turnover | 1.88x |
| Cash Conversion Cycle | 151 days |
Scores
BIOX has an Altman Z-Score of -0.84, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -0.84 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $246.31M over the last 12 months is down 24.33% from the 12 months before.
| Revenue | $246.31M |
|---|---|
| Revenue Growth (YoY) | -24.33% |
| Gross Profit | $87.26M |
| Operating Income | -$1.01M |
| Pretax Income | -$54.23M |
| Net Income | -$230.17M |
| EBITDA | $2.66M |
| EBIT | -$41.22M |
| Reported EPS (TTM) | -$0.88 |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
Shareholder equity funds 8.30% of the $471.30M in total assets.
| Cash and Equivalents | $11.20M |
|---|---|
| Total Debt | $229.20M |
| Net Debt | $218.00M |
| Net Debt Per Share | $3.43 |
| Working Capital | -$51.80M |
| Shareholder Equity | $39.10M |
| Book Value Per Share | $0.61 |
| Tangible Book Value | -$79.20M |
| Total Assets | $471.30M |
| Total Liabilities | $407.20M |
Balance sheet as of Jun 30, 2026.
Cash Flow
| Capital Expenditures | $1.59M |
|---|---|
| FCF Per Share | $1.13 |
Trailing 12 months through Jun 30, 2026.
Margins
The operating margin is -0.41%, against a 5-year average of 6.78%.
| Gross Margin | 35.43% |
|---|---|
| Operating Margin | -0.41% |
| Pretax Margin | -22.02% |
| Net Margin | -93.45% |
| EBITDA Margin | 1.08% |
| EBIT Margin | -16.73% |
| Gross Margin (5Y Average) | 38.52% |
| Operating Margin (5Y Average) | 6.78% |
| Net Margin (5Y Average) | -22.10% |
Growth
Revenue fell 17.24% a year over 3 years.
| Revenue Growth (3Y CAGR) | -17.24% |
|---|---|
| Revenue Growth (5Y CAGR) | +2.84% |
| Operating Income Growth (3Y CAGR) | -87.64% |
| Book Value Per Share Growth (2Y CAGR) | -64.73% |
Dividends and Yields
BIOX does not pay a dividend. Its free cash flow yield is 597.12%.
| FCF Yield | 597.12% |
|---|---|
| Shareholder Yield | 0.00% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About BIOX
What is BIOX's market cap?
Bioceres Crop Solutions has a market cap of $12.74M. Its enterprise value, which adds debt and subtracts cash, is $230.74M.
How many shares of BIOX are outstanding?
Bioceres Crop Solutions has 63.60M shares outstanding. The count is up 0.63% from a year earlier.
Does BIOX pay a dividend?
No. Bioceres Crop Solutions does not pay a dividend.
How much debt does BIOX have?
Bioceres Crop Solutions has $229.20M of total debt and $11.20M of cash and equivalents, a net debt position of $218.00M.
BIOX pages: Overview, Charting, Earnings, Financials, Statistics